UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of January 2024
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
 18 January 2024 - “Holding(s) in Company”
 
 
 
 
99.1
 
 
 
 
18 January 2024
 
HALEON PLC
("Haleon" or "the Company")  
 
TR-1: Standard form for notification of major holdings  
1. Issuer Details
 
ISIN
GB00BMX86B70
 
 
Issuer Name
HALEON PLC
 
 
UK or Non-UK Issuer
UK
 
 
2. Reason for Notification
 
An acquisition or disposal of voting rights
 
 
3. Details of person subject to the notification obligation
 
Name
GSK plc
 
 
City of registered office (if applicable)
BRENTFORD
 
 
Country of registered office (if applicable)
United Kingdom
 
 
Name
City of registered office
Country of registered office
GSK (No.1) Scottish Limited Partnership
 
Edinburgh
 
Scotland
 
GSK LP Limited
 
London
 
England
 
GSK GP 1 Limited
 
Edinburgh
 
Scotland
 
 
4. Details of the shareholder
 
Name
City of registered office
Country of registered office
Vidacos Nominees Limited
 
London
 
England
 
 
5. Date on which the threshold was crossed or reached
 
17-Jan-2024
 
 
6. Date on which Issuer notified
 
18-Jan-2024
 
 
7. Total positions of person(s) subject to the notification obligation
 
 
% of voting rights attached to shares (total of 8.A)
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached
 
4.170000
 
0.000000
 
4.170000
 
385320110
 
Position of previous notification (if applicable)
 
7.420000
 
0.000000
 
7.420000
 
 
 
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
 
8A. Voting rights attached to shares
 
Class/Type of shares ISIN code(if possible)
Number of direct voting rights (DTR5.1)
Number of indirect voting rights (DTR5.2.1)
% of direct voting rights (DTR5.1)
% of indirect voting rights (DTR5.2.1)
GB00BMX86B70
 
0
 
385320110
 
0.000000
 
4.170000
 
Sub Total 8.A
385320110
 
4.170000%
 
 
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
 
Type of financial instrument
Expiration date
Exercise/conversion period
Number of voting rights that may be acquired if the instrument is exercised/converted
% of voting rights
 
 
 
 
 
Sub Total 8.B1
 
 
 
 
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
 
Type of financial instrument
Expiration date
Exercise/conversion period
Physical or cash settlement
Number of voting rights
% of voting rights
 
 
 
 
 
 
Sub Total 8.B2
 
 
 
 
9. Information in relation to the person subject to the notification obligation
 
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
 
 
 
Ultimate controlling person
Name of controlled undertaking
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
GSK plc (Chain 1)
 
 
2.850000
 
 
2.850000%
 
GSK plc (Chain 1)
 
GlaxoSmithKline Holdings Limited (Chain 1)
 
2.850000
 
 
2.850000%
 
GSK plc (Chain 1)
 
GlaxoSmithKline Finance plc (Chain 1)
 
2.850000
 
 
2.850000%
 
GSK plc (Chain 1)
 
Glaxo Group Limited (Chain 1)
 
2.850000
 
 
2.850000%
 
GSK plc (Chain 2)
 
 
1.330000
 
 
1.330000%
 
GSK plc (Chain 2)
 
GSK LP Limited (Chain 2)
 
1.330000
 
 
1.330000%
 
GSK plc (Chain 2)
 
GSK GP 1 Limited (Chain 2)
 
1.330000
 
 
1.330000%
 
GSK plc (Chain 2)
 
GSK (No. 1) Scottish Limited Partnership (Chain 2)
 
1.330000
 
 
1.330000%
 
 
10. In case of proxy voting
 
Name of the proxy holder
 
 
 
The number and % of voting rights held
 
 
 
The date until which the voting rights will be held
 
 
 
11. Additional Information
 
GSK plc is making this notification on behalf of itself and on behalf of GSK LP Limited, GSK GP 1 Limited and GSK (No.1) Scottish Limited Partnership.
 
This notification relates to the sale by GSK (No.1) Scottish Limited Partnership (an entity indirectly wholly-owned by GSK plc) of a portion of its interest in Haleon plc.
 
GSK GP 1 Limited is the sole general partner of GSK (No.1) Scottish Limited Partnership.
 
GSK LP Limited is the sole limited partner of GSK (No.1) Scottish Limited Partnership.Glaxo Group Limited and GSK (No.1) Scottish Limited Partnership hold their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which holds the legal title to those shares on their behalf pursuant to a custody arrangement.
 
 
12. Date of Completion
 
18-Jan-2024
 
 
13. Place Of Completion
 
London, England
 
 
Amanda Mellor, Company Secretary
 
 
 
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: January 18, 2024
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary
 
 

Haleon (NYSE:HLN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Haleon Charts.
Haleon (NYSE:HLN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Haleon Charts.